Boundless Bio (BOLD) Non Operating Income (2023 - 2026)
Boundless Bio (BOLD) posted quarterly Non Operating Income of $920000.0 for Q1 2026, down 41.88% year-over-year from $1.6 million in Q1 2025, and down 17.64% quarter-over-quarter from $1.1 million in Q4 2025.
Boundless Bio (BOLD) Non Operating Income (2023 - 2026) Analysis & Trends
Boundless Bio (BOLD) has reported Non Operating Income for 4 consecutive years, with $920000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 41.88% year-over-year to $920000.0; the TTM figure through Mar 2026 stood at $4.7 million (down 41.6% YoY), while the FY2025 annual figure was $5.4 million, down 32.25% from the prior year.
- Non Operating Income retreated to $920000.0 in Q1 2026 per BOLD's latest filing, from $1.1 million in the prior quarter.
- Across five years, Non Operating Income topped out at $2.4 million in Q2 2024 and bottomed at $368000.0 in Q1 2023.
- Historically, Non Operating Income has averaged $1.5 million across 4 years, with a median of $1.6 million in 2023.
- Annual changes were most pronounced in 2024 — Non Operating Income surged 294.84% — and 2025, when it tumbled 42.61%.
- Boundless Bio's Non Operating Income stood at $1.7 million in 2023, then gained by 10.77% to $1.8 million in 2024, then tumbled by 38.96% to $1.1 million in 2025, then slipped by 17.64% to $920000.0 in 2026.
- Business Quant data shows BOLD's Non Operating Income at $920000.0 in Q1 2026, $1.1 million in Q4 2025, and $1.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.40 Bn | 131.55 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 65.20 Bn | 60.02 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.40 Bn | 55.26 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.17 Bn | 37.07 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.36 Bn | 28.05 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.74 Bn | 10.34 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.45 Bn | 26.29 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.17 Bn | 26.33 Bn | - | -51.63 Mn |
| 10 | Boundless Bio | 67.57 Mn | 67.57 Mn | - | 691,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 691,000.00 |
| Mar 31, 2026 | 920,000.00 |
| Dec 31, 2025 | 1.12 Mn |
| Sep 30, 2025 | 1.27 Mn |
| Jun 30, 2025 | 1.39 Mn |
| Mar 31, 2025 | 1.58 Mn |
| Dec 31, 2024 | 1.83 Mn |
| Sep 30, 2024 | 2.21 Mn |
| Jun 30, 2024 | 2.42 Mn |
| Mar 31, 2024 | 1.45 Mn |
| Dec 31, 2023 | 1.65 Mn |
| Sep 30, 2023 | 1.78 Mn |
| Jun 30, 2023 | 1.56 Mn |
| Mar 31, 2023 | 368,000.00 |